Balancing Accelerated Approval for Drugs With Accelerated Withdrawal Reply

被引：0
|
作者：
Kim, Chul [1 ]
Prasad, Vinay [2 ,3 ]
机构：
[1] NCI, Med Oncol Serv, NIH, Bethesda, MD 20892 USA
[2] Oregon Hlth & Sci Univ, Div Hematol Oncol, Knight Canc Inst, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Ctr Hlth Care Eth, Portland, OR 97239 USA
来源：
JAMA INTERNAL MEDICINE | 2016年 / 176卷 / 04期
关键词：
D O I：
10.1001/jamainternmed.2016.0374
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：567 / 567
页数：1
相关论文
共 50 条
  • [41] Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval
    Liu, Ian T. T.
    Kesselheim, Aaron S.
    Cliff, Edward R. Scheffer
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (17): : 1471 - 1479
  • [42] Confirmatory Trials of Accelerated Approval Drugs - Will Imposing Fines Reduce Delays?
    Daval, C. Joseph Ross
    Kesselheim, Aaron S.
    Scheffer Cliff, Edward R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [43] Drugs for dementia should receive accelerated approval, says world envoy
    Limb, Matthew
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
  • [44] Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab
    Papachristos, Apostolos
    Ratain, Mark J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (01) : 29 - 31
  • [45] Limiting Medicaid Access to Accelerated Approval Drugs: Costs and Consequences COMMENT
    Thorpe, Kenneth E.
    Holtz-Eakin, Douglas
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (06): : E178 - E180
  • [46] Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
    Kato, Satoshi
    Ono, Shunsuke
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2024, 19 (05)
  • [47] Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
    Hwang, T.
    Molto, C.
    Puy, M. Borrell
    Tibau, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S931 - S931
  • [48] Slowing down accelerated approval
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (03) : 165 - 165
  • [49] Accelerated approval requirements for lurbinectedin
    Benjamin, David J.
    Prasad, Vinay
    LANCET ONCOLOGY, 2022, 23 (05): : E206 - E206
  • [50] Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway
    Shahzad, Mahnum
    Naci, Huseyin
    Wagner, Anita K.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (09): : 760 - 761
12345